Literature DB >> 7871066

Raclopride, but not SCH 23,390, induces maldirected jumping in rats trained to perform a run-climb-run behavioral task.

L Senyuz1, S C Fowler.   

Abstract

In order to explore further the putative differential behavioral consequences of D1 dopamine and D2 dopamine receptor antagonism, SCH 23,390 (0.01-0.12 mg/kg) and raclopride (0.12-1.0 mg/kg) were administered to two separate groups of rats that had been trained in an eight-trial-per-day format to run down an alleyway, climb a vertical rope, and run across a horizontal board to access sweetened milk. Although both drugs dose-dependently reduced the speed of task completion, only raclopride produced vigorous, maldirected jumping behavior in the floor segment of the apparatus. The number of such jumps increased with dose. This raclopride-specific jumping phenomenon may provide a new behavioral arena for investigating the functional differences between D1 and D2 receptor antagonism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7871066     DOI: 10.1007/bf02244903

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

Review 2.  The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia.

Authors:  C R Gerfen
Journal:  Annu Rev Neurosci       Date:  1992       Impact factor: 12.449

3.  Anticholinergic drugs potentiate dopamine D1 but not D2 antagonists on a conditioned avoidance task in rats.

Authors:  L C Iorio; M Cohen; V L Coffin
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

4.  Seemingly paradoxical jumping in cataleptic haloperidol-treated rats is triggered by postural instability.

Authors:  T K Morrissey; S M Pellis; V C Pellis; P Teitelbaum
Journal:  Behav Brain Res       Date:  1989-12-01       Impact factor: 3.332

Review 5.  Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist.

Authors:  J L Waddington; K M O'Boyle
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

6.  SCH 23390 - the first selective dopamine D-1 antagonist.

Authors:  J Hyttel
Journal:  Eur J Pharmacol       Date:  1983-07-15       Impact factor: 4.432

7.  Effects of haloperidol on a run-climb-run behavioral task: distance climbed does not alter within-session decrements.

Authors:  S C Fowler; L Senyuz
Journal:  Behav Neurosci       Date:  1993-08       Impact factor: 1.912

8.  Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride.

Authors:  L Farde
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.

Authors:  L C Iorio; A Barnett; F H Leitz; V P Houser; C A Korduba
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

10.  The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.

Authors:  S O Ogren; H Hall; C Köhler; O Magnusson; S E Sjöstrand
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  10 in total
  1 in total

1.  Microcatalepsy and disruption of forelimb usage during operant behavior: differences between dopamine D1 (SCH-23390) and D2 (raclopride) antagonists.

Authors:  S C Fowler; J R Liou
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.